(MedPage Today) — Multiple sclerosis (MS) patients treated with ocrelizumab (Ocrevus) had a higher risk of infections over time than other MS patients, a real-world cohort study showed.
The risk for serious infection was higher (OR 1.98, 95…
Source link : https://www.medpagetoday.com/meetingcoverage/ectrims/117680
Author :
Publish date : 2025-09-28 14:54:00
Copyright for syndicated content belongs to the linked Source.
